Exogenus Therapeutics - Exosome based therapeutics

ABOUT US

Exogenus Therapeutics is a drug development company using an exosome-based platform technology to develop an innovative pipeline of therapeutic products. Leveraging on the strong regenerative, anti-inflammatory and immunomodulatory properties of our proprietary vesicles, we are developing a pipeline of products for skin and autoimmune diseases.

WHO WE ARE

The company was founded by two researchers, Joana Simões Correia and Ricardo Neves and one manager, Luísa Marques. The project that led to the creation of the company (Nanoinspire) participated in COHiTEC 2014 program and is the result of the research developed in collaboration between the Centre for Neurosciences and Cellular Biology of Coimbra University, Crioestaminal SA, and Biocant. Founded in June 2015, the company has so far secured €1M funding, of which €900K from venture capital firms, and in excess of €600K from a Portugal 2020 R&D grant.
Exo-T received the Young Entrepreneur Award by ANJE in 2015, and the Everis Award in 2016. In the same year, the company obtained the SME Instrument Phase 1 support from the European Commission, and in 2017 the company was a finalist of the Alira Health - EWMA (European Wound Management Association) Award, recognizing Exo-T as one of the top 5 most Innovative Companies worldwide in wound care.